Algomedix Competitors and Similar CompaniesClear all
 Algomedix Algomedix is a company engaged in the development of Transient Receptor Potential (TRP) therapeutics to treat serious medical needs, including chronic and acute pain. |  CTI BioPharma CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. |  NeurOp NeurOp is a biotechnology company developing medicines for the treatment of central nervous system (CNS) disorders including stroke, severe pain, subarachnoid hemorrhage (SAH), and treatment-resistant depression. |  Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company that develops and commercializes therapeutics for rare endocrine diseases and endocrine-related tumors. |  Acticor Biotech Acticor Biotech is a biopharmaceutical company developing an antithrombotic agent for the treatment of the acute phase of ischemic stroke. | |
Founding Date | Founding Date 2010 | Founding Date 1992 | Founding Date 2002 | Founding Date 2008 | Founding Date 2013 |
Type | Type Private | Type Public | Type Private | Type Public | Type Private |
Tags | |||||
Locations | Locations Mill Creek, US HQ | Locations Seattle, US HQ Köln, DE | Locations Atlanta, US HQ | Locations San Diego, US HQ | Locations Paris, FR HQ Paris, FR |
Employees | Employees 1 | Employees 2546% decrease | Employees 6 | Employees 43751% increase | Employees 1711% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.2 b | Valuation ($) N/A | Valuation ($) 5.1 b | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $53.9m (FY, 2022) | Revenue (est.) N/A | Revenue (est.) $7.7m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $3.5m (FY, 2022) | Cost of goods N/A | Cost of goods $1.1m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $50.4m (FY, 2022) | Gross profit N/A | Gross profit $6.6m (FY, 2025) | Gross profit N/A |
Net income | Net income N/A | Net income ($93m) (FY, 2022) | Net income N/A | Net income ($465.3m) (FY, 2025) | Net income N/A |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 155k (over 12 years ago) | Latest funding round N/A | Latest funding round $ 7.8m (over 6 years ago) |
Total funding raised | Total funding raised N/A | Total funding raised $ 105m | Total funding raised N/A | Total funding raised $ 41.5m | Total funding raised $ 33.3m |
View Company Profiles
CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers.
View companyNeurOp is a biotechnology company developing medicines for the treatment of central nervous system (CNS) disorders including stroke, severe pain, subarachnoid hemorrhage (SAH), and treatment-resistant depression.
View companyCrinetics Pharmaceuticals is a clinical-stage pharmaceutical company that develops and commercializes therapeutics for rare endocrine diseases and endocrine-related tumors.
View companyActicor Biotech is a biopharmaceutical company developing an antithrombotic agent for the treatment of the acute phase of ischemic stroke.
View company